{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Run-in Period Diet Equilibration",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "First Dose",
        "windowLower": -7,
        "windowUpper": -5
      },
      {
        "id": "timing_2",
        "name": "Pretreatment Copper Balance Measurement",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose",
        "windowLower": -4,
        "windowUpper": -1
      },
      {
        "id": "timing_3",
        "name": "Treatment Period 1 Duration",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_4",
        "name": "Dose Titration to 30mg",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_5",
        "name": "CRU Admission for Treatment Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_6",
        "name": "Potential Discharge from CRU",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 9,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_7",
        "name": "Return to CRU for Treatment Period 2",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 1
      },
      {
        "id": "timing_8",
        "name": "Outpatient Period Extension",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 14
      },
      {
        "id": "timing_9",
        "name": "End of Study Visit",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_10",
        "name": "Initial 15mg Collection Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 8,
        "relativeTo": "First Dose",
        "windowLower": 1,
        "windowUpper": 8
      },
      {
        "id": "timing_11",
        "name": "Second Collection Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 15,
        "relativeTo": "First Dose",
        "windowLower": 25,
        "windowUpper": 39
      },
      {
        "id": "timing_12",
        "name": "Steady State Achievement",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_13",
        "name": "Zinc Discontinuation Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose",
        "windowLower": -21,
        "windowUpper": 0
      },
      {
        "id": "timing_14",
        "name": "Chelator Discontinuation Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose",
        "windowLower": -4,
        "windowUpper": 0
      },
      {
        "id": "timing_15",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "Study Start",
        "windowLower": -14,
        "windowUpper": 0
      },
      {
        "id": "timing_16",
        "name": "Non-prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7,
        "relativeTo": "Study Start",
        "windowLower": -7,
        "windowUpper": 0
      },
      {
        "id": "timing_17",
        "name": "Alcohol Abstinence Before Dosing",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "First Dose",
        "windowLower": -48,
        "windowUpper": 0
      },
      {
        "id": "timing_18",
        "name": "Overnight Fast Before Dosing",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "First Dose",
        "windowLower": -10,
        "windowUpper": 0
      },
      {
        "id": "timing_19",
        "name": "Post-dose Meal Delay",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "First Dose",
        "windowLower": 2,
        "windowUpper": 0
      },
      {
        "id": "timing_20",
        "name": "SRC Safety Data Review",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 23,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_21",
        "name": "Inpatient Period 2 Duration",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 18,
        "relativeTo": "First Dose",
        "windowLower": 23,
        "windowUpper": 40
      },
      {
        "id": "timing_22",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening",
        "windowLower": -90,
        "windowUpper": 0
      },
      {
        "id": "timing_23",
        "name": "Previous ALXN1840 Washout",
        "type": "Before",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose",
        "windowLower": -365,
        "windowUpper": 0
      },
      {
        "id": "timing_24",
        "name": "Catheter Maximum Duration",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 72,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 72
      },
      {
        "id": "timing_25",
        "name": "Catheter Flush Interval",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 8,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 8
      },
      {
        "id": "timing_26",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "Previous Visit",
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_27",
        "name": "Urine Void Completion Window",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 2
      },
      {
        "id": "timing_28",
        "name": "Pregnancy Test Interval",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 28
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "ALT Elevation Criteria",
        "instanceType": "Condition",
        "description": "Liver function test abnormality requiring dose modification",
        "text": "ALT > 3 × ULN accompanied by bilirubin > 2 × ULN indicative of liver injury"
      },
      {
        "id": "cond_2",
        "name": "Hemoglobin Decrease Criteria",
        "instanceType": "Condition",
        "description": "Anemia requiring dose modification",
        "text": "Hemoglobin > 20% decrease from baseline"
      },
      {
        "id": "cond_3",
        "name": "Platelet Decrease Criteria",
        "instanceType": "Condition",
        "description": "Thrombocytopenia requiring dose modification",
        "text": "Platelets > 25% decrease from baseline"
      },
      {
        "id": "cond_4",
        "name": "Neutrophil Decrease Criteria",
        "instanceType": "Condition",
        "description": "Neutropenia requiring dose modification",
        "text": "Neutrophils > 30% decrease from baseline"
      },
      {
        "id": "cond_5",
        "name": "Neurological Worsening Criteria",
        "instanceType": "Condition",
        "description": "Evidence of neurologic deterioration",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_6",
        "name": "Psychiatric Worsening Criteria",
        "instanceType": "Condition",
        "description": "Acute psychiatric deterioration",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis"
      },
      {
        "id": "cond_7",
        "name": "SRC Safety Review Approval",
        "instanceType": "Condition",
        "description": "Safety Review Committee approval for dose titration",
        "text": "Before titration to 30 mg/day, the Safety Review Committee will review available safety data through Day 23 for each participant"
      },
      {
        "id": "cond_8",
        "name": "Age Eligibility",
        "instanceType": "Condition",
        "description": "Age requirement for study participation",
        "text": "Male or female participants aged 18 to 65 years"
      },
      {
        "id": "cond_9",
        "name": "Wilson Disease Diagnosis",
        "instanceType": "Condition",
        "description": "Confirmed WD diagnosis requirement",
        "text": "Documented diagnosis of WD by Leipzig score ≥ 4"
      },
      {
        "id": "cond_10",
        "name": "Renal Function Criteria",
        "instanceType": "Condition",
        "description": "Adequate renal function requirement",
        "text": "Creatinine clearance ≥ 30 mL/min, not on dialysis"
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Run-in to Treatment Period 1",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_runin",
        "toElementId": "epoch_treatment1",
        "text": "Following screening and enrollment, participants will have a Run-in Period to support diet equilibration (Day -7 through Day -5) and measurement of pretreatment copper and molybdenum balance (Day -4 through Day -1)"
      },
      {
        "id": "trans_2",
        "name": "15mg to 30mg Dose Titration",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "Participants will be administered ALXN1840 at 15 mg/day on Day 1 through Day 28 and then increase to 30 mg/day on Day 29 through Day 39"
      },
      {
        "id": "trans_3",
        "name": "ALT Elevation Dose Reduction",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "ALT > 3 × ULN: Reduce dose to previous dose level if up-titration has occurred or reduce dose to 15 mg QOD if on 15 mg QD"
      },
      {
        "id": "trans_4",
        "name": "Hemoglobin Decrease Dose Reduction",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Hemoglobin > 20% decrease from baseline: Reduce dose to previous dose level if up-titration has occurred or reduce dose to 15 mg QOD if on 15 mg QD"
      },
      {
        "id": "trans_5",
        "name": "Platelet Decrease Dose Reduction",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Platelets > 25% decrease from baseline: Reduce dose to previous dose level if up-titration has occurred or reduce dose to 15 mg QOD if on 15 mg QD"
      },
      {
        "id": "trans_6",
        "name": "Neutrophil Decrease Dose Reduction",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Neutrophils > 30% decrease from baseline: Reduce dose to previous dose level if up-titration has occurred or reduce dose to 15 mg QOD if on 15 mg QD"
      },
      {
        "id": "trans_7",
        "name": "Bilirubin Elevation Temporary Interruption",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Bilirubin > 2 × ULN accompanied by ALT > 3 × ULN: Temporary interruption with weekly repeat testing"
      },
      {
        "id": "trans_8",
        "name": "Serious Hypersensitivity Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if serious hypersensitivity reaction occurs"
      },
      {
        "id": "trans_9",
        "name": "Severe Infection Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if severe uncontrolled infection occurs"
      },
      {
        "id": "trans_10",
        "name": "Disallowed Medication Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if use of disallowed medication occurs"
      },
      {
        "id": "trans_11",
        "name": "Pregnancy Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if pregnancy or planned pregnancy occurs"
      },
      {
        "id": "trans_12",
        "name": "Inpatient to Outpatient Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_inpatient1",
        "toElementId": "epoch_outpatient",
        "text": "Participants may be discharged from the CRU on Day 9 to return on Day 22 or Day 23"
      },
      {
        "id": "trans_13",
        "name": "Outpatient to Inpatient Period 2",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_outpatient",
        "toElementId": "epoch_inpatient2",
        "text": "Participants will be re-admitted on Day 22 or Day 23 for Treatment Period 2 and will remain in house until Day 40"
      },
      {
        "id": "trans_14",
        "name": "Rechallenge After Dose Interruption",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Rechallenge at 15 mg QOD or less frequent when parameters return to baseline. A maximum of 3 rechallenges will be allowed"
      },
      {
        "id": "trans_15",
        "name": "Post-Study Therapy Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_followup",
        "text": "Following completion of both inpatient periods (Day 40), participants will transition to therapy that was discontinued before enrollment, or transition to other standard of care therapy, or consider continuation of ALXN1840 treatment"
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Participant Voluntary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request"
      },
      {
        "id": "exit_2",
        "name": "Investigator Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons"
      },
      {
        "id": "exit_3",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities"
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site after 3 telephone calls and certified letter"
      },
      {
        "id": "exit_5",
        "name": "Study Intervention Discontinuation",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "If the study intervention is definitively discontinued, the participant should remain in the study to be evaluated for safety follow-up"
      },
      {
        "id": "exit_6",
        "name": "Site Closure",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason"
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "SRC Dose Titration Decision",
        "timepointId": "day_23",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Safety Review Committee reviews available safety data through Day 23 for each participant before titration to 30 mg/day",
        "conditionIds": [
          "cond_7"
        ]
      },
      {
        "id": "dec_2",
        "name": "ALT Dose Modification Decision",
        "timepointId": "any_visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for dose reduction or interruption based on ALT elevation",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_3",
        "name": "Hematology Dose Modification Decision",
        "timepointId": "any_visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for dose reduction based on hemoglobin, platelet, or neutrophil decreases",
        "conditionIds": [
          "cond_2",
          "cond_3",
          "cond_4"
        ]
      },
      {
        "id": "dec_4",
        "name": "Neurological Assessment Decision",
        "timepointId": "any_visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Investigator and Alexion Medical Monitor evaluate need for dose modification based on neurologic worsening",
        "conditionIds": [
          "cond_5"
        ]
      },
      {
        "id": "dec_5",
        "name": "Psychiatric Assessment Decision",
        "timepointId": "any_visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Investigator and Alexion Medical Monitor evaluate need for dose modification based on psychiatric worsening",
        "conditionIds": [
          "cond_6"
        ]
      },
      {
        "id": "dec_6",
        "name": "Outpatient Period Extension Decision",
        "timepointId": "day_9",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Investigator approval required to extend Outpatient Period up to an additional 14 days"
      },
      {
        "id": "dec_7",
        "name": "CRU Retention Decision",
        "timepointId": "day_9",
        "instanceType": "ScheduledDecisionInstance",
        "description": "At the CRU's discretion, participants may remain in the CRU during the outpatient period for safety or to maintain the integrity of the conduct of the study"
      },
      {
        "id": "dec_8",
        "name": "Rechallenge Decision",
        "timepointId": "any_visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to rechallenge after dose interruption when parameters return to baseline, maximum 3 rechallenges allowed",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3",
          "cond_4"
        ]
      }
    ],
    "summary": {
      "timingCount": 28,
      "conditionCount": 10,
      "transitionRuleCount": 15,
      "exitCount": 6
    }
  }
}